Company Overview
About Menten AI
Menten AI is a San Francisco-based AI drug discovery company — backed by Y Combinator (W20) with $4.15 million in total funding from Y Combinator, Khosla Ventures, Uncork Capital, Feld Ventures, Mana Ventures, Quain Investments, Society Health, and Volpini Ventures — developing peptide and protein therapeutics using machine learning and quantum computing to design novel cyclic peptide drug candidates for pharmaceutical licensing partnerships, completing a research collaboration with Bristol Myers Squibb in May 2024. Founded in 2018, Menten AI applies advanced AI algorithms for cyclic peptide optimization and protein structure design with a business model centered on licensing proprietary algorithms and drug candidates to pharma partners rather than developing therapeutics through full clinical development.
Business Model & Competitive Advantage
Menten AI's AI peptide design platform addresses the molecular optimization challenge in macrocyclic peptide drug discovery: cyclic peptides (peptides where the chain forms a ring structure rather than a linear sequence) have emerged as a promising drug modality that bridges small molecules (cell-permeable, bioavailable) and biologics (can engage large, flat protein-protein interaction surfaces undruggable by small molecules) — but their design is computationally difficult because the ring conformational space is exponentially larger than linear peptide space, and predicting which conformations will achieve target binding affinity and membrane permeability requires advanced computational methods. Menten AI's ML models (predicting cyclic peptide binding to target proteins, membrane permeability, metabolic stability, and pharmacokinetic properties) accelerate the design-make-test cycle for cyclic peptide drug discovery by predicting which candidates will succeed before expensive synthesis and testing.
Competitive Landscape 2025–2026
In 2025, Menten AI competes in the AI drug discovery, cyclic peptide therapeutics, and computational chemistry market with PepGen (cyclic peptide therapeutics, NASDAQ: PEPG, $300M raised), Aileron Therapeutics (stapled peptides, NASDAQ: ALRN), and Relay Therapeutics (NASDAQ: RLAY, computational drug design, $700M raised) for pharmaceutical partner AI-assisted cyclic peptide drug candidate licensing and computational design collaboration adoption. Khosla Ventures' and Uncork Capital's investments reflect deep-tech drug discovery conviction. The Bristol Myers Squibb collaboration (BMS is a top-5 global pharmaceutical company with $45B+ revenue) validates Menten AI's platform quality for industry-grade peptide design. Y Combinator W20 backing positions Menten AI within the computational biology and AI drug discovery investment community. The 2025 strategy focuses on advancing the pipeline of cyclic peptide candidates for oncology and infectious disease targets, building the quantum computing-enhanced conformational sampling for improved prediction accuracy, and expanding the pharma partnership model with additional top-20 pharmaceutical company collaborations.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Menten AI is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Cursor
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir
Kindful
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid
Compare Menten AI with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Menten AI? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Menten AI Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Menten AI vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →